Flt-1/VEGFR1 Antibody (D-2): sc-271789

VEGFR1 Antibody (D-2) is a mouse monoclonal IgG1 kappa light chain antibody that detects VEGFR1 of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). VEGFR1 (D-2) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. VEGFR1, also known as Flt-1, plays a crucial role in angiogenesis by serving as a high-affinity receptor for vascular endothelial growth factors (VEGFs), which are essential for the formation of new blood vessels. This function is particularly important in both normal physiological processes, such as wound healing and tissue repair, and in pathological conditions, including cancer, where tumor growth is often dependent on the development of a robust blood supply. VEGFR1′s ability to bind VEGF not only influences endothelial cell proliferation and migration but also modulates the activity of other receptors in the VEGF family, thereby impacting vascular permeability and the overall angiogenic response. Understanding VEGFR1′s role in these processes can provide insights into therapeutic strategies aimed at inhibiting angiogenesis in diseases characterized by excessive blood vessel formation.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Flt-1/VEGFR1 Antibody (D-2) References:

1. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.  |  de Vries, C., et al. 1992. Science. 255: 989-91. PMID: 1312256
2. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.  |  Kaplan, RN., et al. 2005. Nature. 438: 820-7. PMID: 16341007
3. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit.  |  Matthews, W., et al. 1991. Proc Natl Acad Sci U S A. 88: 9026-30. PMID: 1717995
4. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family.  |  Shibuya, M., et al. 1990. Oncogene. 5: 519-24. PMID: 2158038
5. VEGFR1 signaling in retinal angiogenesis and microinflammation.  |  Uemura, A., et al. 2021. Prog Retin Eye Res. 84: 100954. PMID: 33640465
6. HIF-1α inhibitor YC-1 suppresses triple-negative breast cancer growth and angiogenesis by targeting PlGF/VEGFR1-induced macrophage polarization.  |  Li, Y., et al. 2023. Biomed Pharmacother. 161: 114423. PMID: 36822023
7. A defined clathrin-mediated trafficking pathway regulates sFLT1/VEGFR1 secretion from endothelial cells.  |  Kinghorn, K., et al. 2024. Angiogenesis. 27: 67-89. PMID: 37695358
8. Targeting NGF but not VEGFR1 or BDNF signaling reduces endometriosis-associated pain in mice.  |  Zaninelli, TH., et al. 2024. J Adv Res.. PMID: 39142441
9. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis.  |  Millauer, B., et al. 1993. Cell. 72: 835-46. PMID: 7681362
10. Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth.  |  Peters, KG., et al. 1993. Proc Natl Acad Sci U S A. 90: 8915-9. PMID: 7692439
11. The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor.  |  Galland, F., et al. 1993. Oncogene. 8: 1233-40. PMID: 8386825
12. NYK/FLK-1: a putative receptor protein tyrosine kinase isolated from E10 embryonic neuroepithelium is expressed in endothelial cells of the developing embryo.  |  Oelrichs, RB., et al. 1993. Oncogene. 8: 11-8. PMID: 8423988

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Flt-1/VEGFR1 Antibody (D-2) has 27 citations in a variety of scientific publications.

Primary antibodies like Anti-Flt-1/VEGFR1 Antibody (D-2) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Flt-1/VEGFR1 Antibody (D-2) Specifications

Alternate Product Name: VEGFR1

Product Clone Name: D-2

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 23-247

Epitope Target: VEGFR1

Epitope Species: human

Product Reactivity/Detection: VEGFR1

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 27 citations in various scientific publications

Available Conjugates/Forms for Flt-1/VEGFR1 Antibody (D-2): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin